Page last updated: 2024-12-08
formyl-leurosine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
formyl-leurosine: RN given refers to (3'alpha,4'alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 320745 |
| SCHEMBL ID | 2034392 |
| MeSH ID | M0066449 |
Synonyms (12)
| Synonym |
|---|
| nsc269419 |
| vincaleukoblastine,4'-epoxy-22-oxo-, (3'.alpha.,4'.alpha.)- |
| formyl-leurosine |
| formylleurosine |
| n-formyl leurosine (vincristine impurity g) |
| GLDSBTCHEGZWCV-HLTPFJCJSA-N |
| SCHEMBL2034392 |
| AKOS030242406 |
| methyl (13s,15r,16r,18s)-13-[(1r,9r,10s,11r,12r,19r)-11-acetyloxy-12-ethyl-8-formyl-10-hydroxy-5-methoxy-10-methoxycarbonyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-18-ethyl-17-oxa-1,11-diazapentacyclo[13.4.1.04,12.05,1 |
| 22-oxo-o~3'~,3'-cyclovincaleukoblastine |
| DTXSID60968854 |
| (3'a,4'a)-4'-deoxy-3',4'-epoxy-22-oxovincaleukoblastine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||